Multicenter, Open-Label Study of Long-Term Administration of Febuxostat (TMX-67) in Japanese Patients With Hyperuricemia Including Gout
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JCR: Journal of Clinical Rheumatology
- Vol. 17 (4), S50-S56
- https://doi.org/10.1097/rhu.0b013e31822541d0
Abstract
In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6.0 mg/dL or less in about 80% of patients treated with 40 mg/d febuxostat, a nonpurine selective xanthine oxidase inhibitor, a few patients did not show this result. The objective of the study was to evaluate the efficacy and safety of long-term febuxostat administration at up to 60 mg/d in patients with hyperuricemia and gout. In a 52-week, multicenter, open-label trial, febuxostat was initially administered at 10 mg/d; then, the dosage was increased in a stepwise fashion to 40 mg/d. For sUA levels greater than 6.0 mg/dL at week 10, the dosage was increased to 60 mg/d from week 14 onward (60-mg group), but it was maintained at 40 mg/d until the end of the study for patients with sUA levels 6.0 mg/dL or less at week 10 (40-mg group). The sUA levels in both groups decreased dose dependently. At 52 weeks, 84.5% and 85.0% of the 40- and 60-mg groups, respectively, achieved mean sUA levels 6.0 mg/dL or less. There was no marked difference between the 2 dosage groups in terms of the incidence of adverse events. Furthermore, there were no noteworthy adverse events or adverse drug reactions in the patients with renal dysfunction, and no differences in drug efficacy up to 60 mg/d were noted between the patients with moderate or mild renal dysfunction and those with normal renal function. Febuxostat seems to be a promising therapeutic drug for gout or hyperuricemia, even in patients with renal dysfunction.Keywords
This publication has 24 references indexed in Scilit:
- Asymptomatic Hyperuricemia: Impact of UltrasonographyNucleosides, Nucleotides and Nucleic Acids, 2008
- A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Care & Research, 2004
- Does hyperuricemia aeffect mortality? A prospective cohort study of Japanese male workers.Journal of Epidemiology, 2000
- Relation of Serum Uric Acid to Mortality and Ischemic Heart DiseaseAmerican Journal of Epidemiology, 1995
- Uric AcidJAMA, 1993
- Gout and coronary heart disease: The framingham studyJournal of Clinical Epidemiology, 1988
- HYPERURICEMIA AS A RISK FACTOR OF CORONARY HEART DISEASE: THE FRAMINGHAM STUDYAmerican Journal of Epidemiology, 1985
- Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiencyAmerican Journal Of Medicine, 1984
- Serum uric acid and coronary heart diseaseAmerican Heart Journal, 1983
- Correlations among hyperuricemia, hypercholesterolemia, coronary disease and hypertensionArthritis & Rheumatism, 1965